Development of a SEMA3C targeted therapeutic for treatment of clear cell renal cell carcinoma, lung cancer, breast cancer and colorectal cancer
The major focus of this proposal is to perform preclinical studies to support clinical development of a novel inhibitor for treatment of different caners such as breast, lung, colorectal and kidney. We have recently developed a novel therapeutic protein that selectively inhibits multiple pathways for treatment of advanced prostate cancer. A goal of this project will be to explore the potential utility of this protein in treatment of cancers for which the inhibitors of these pathways have been clinically validated targets and drugs targeting these pathways are effective in their treatment and have received regulatory approval. These proposed studies will help guide clinical trial design and inclusion criteria for first-in-human clinical trials and future evaluation of biologically-rational combination strategies.